BIW 8962 / Kyowa Kirin - LARVOL DELTA

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma (clinicaltrials.gov) - P1 | N=23 | Terminated | Sponsor: Kyowa Kirin Co., Ltd. | Phase classification: P1/2 ➔ P1

Monotherapy • Phase classification • Hematological Malignancies • Multiple Myeloma • Oncology

BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study (WCLC 2017) - "This study was prematurely terminated due to lack of efficacy, for which the reason is unknown. Clinical development of BIW-8962 has been discontinued."

P1/2 data • Melanoma • Mesothelioma • Multiple Myeloma • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Small Cell Lung Cancer

Two-Part, Open-Label, Multi-Center, Phase 1/2 Study of BIW-8962 as Monotherapy in Subjects With Lung Cancer (clinicaltrials.gov) - P1/2; N=37; Terminated; Sponsor: Kyowa Hakko Kirin Korea Co., Ltd.; N=64 ➔ 37; Active, not recruiting ➔ Terminated

Enrollment change • Trial termination • Biosimilar • Mesothelioma • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer